Small cell lung cancer: From the laboratory to the clinic

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Radiation therapy may be made more effective for SCLC by modifying dose fractionation, based on laboratory observation that SCLC cell lines are often relatively deficient in the ability to recover from doses of 2 Gy or less. Results of this approach will be known within a year. Radiation damage to the lungs may be reduced through the use of agents like PTX which can inhibit production of TNF, a likely initial mediator of radiation-related toxicity. Chemotherapy effectiveness may be improved by building on the observation that etoposide is a schedule dependent drug for SCLC lines, now confirmed in part by clinical trials. The ability to detect low orders of contamination by SCLC cells in marrow or blood should make possible more rational evaluation of outcome in protocols that utilize highdose chemotherapy plus autologons blood products as a consolidation maneuver. The monoclonal antibodies which permit this defection may themselves be of value in 'purging' unwanted tumor cells from these collections. It may soon become practical to eliminate amplified genes which are associated with drug resistance and/or confer a further growth advantage on tumor cells, through the use of agents like hydroxyurea that can selectively eliminate extrachromosomal DNA. The role of recombinant hematopoietic growth factors in SCLC treatment remains unclear at present. Applying the lessons of molecular biology, it may become possible to promote differentiation of SCLC, or at least to prevent its conversion to the variant phenotype associated with increased c-myc expression, with the use of trans-RA or related compounds. 'Broad-spectrum' antagonists of neuropeptide function may be effective and relatively specific inhibitors of autocrine stimulation in SCLC, but toxicity is yet unknown. Finally, biologic response modification may be of use in patients who have had their initial tumor burden reduced by standard therapy, utilizing IL-2 (if it can be made less toxic) or monoclonal antibodies conjugated to a toxin or radioemitter (if they can be made more specific).

Original languageEnglish (US)
Pages (from-to)255-260
Number of pages6
JournalAnticancer Research
Volume14
Issue number1 B
StatePublished - 1994
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Monoclonal Antibodies
Radiation
Dose Fractionation
Drug Therapy
Hydroxyurea
Poisons
Etoposide
Tumor Burden
Neuropeptides
Drug Resistance
Interleukin-2
Molecular Biology
Neoplasms
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Radiotherapy
Bone Marrow
Observation
Clinical Trials

Keywords

  • Dose response
  • Hyperfractionated irradiation
  • Immunotherapy
  • Monoclonal antibodies
  • Recombinant hematopoietic growth factors
  • Retinoids
  • Small cell lung cancer
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Small cell lung cancer : From the laboratory to the clinic. / Livingston, Robert B.

In: Anticancer Research, Vol. 14, No. 1 B, 1994, p. 255-260.

Research output: Contribution to journalArticle

@article{4f9203a84f8d47c19ec774485fdf77b9,
title = "Small cell lung cancer: From the laboratory to the clinic",
abstract = "Radiation therapy may be made more effective for SCLC by modifying dose fractionation, based on laboratory observation that SCLC cell lines are often relatively deficient in the ability to recover from doses of 2 Gy or less. Results of this approach will be known within a year. Radiation damage to the lungs may be reduced through the use of agents like PTX which can inhibit production of TNF, a likely initial mediator of radiation-related toxicity. Chemotherapy effectiveness may be improved by building on the observation that etoposide is a schedule dependent drug for SCLC lines, now confirmed in part by clinical trials. The ability to detect low orders of contamination by SCLC cells in marrow or blood should make possible more rational evaluation of outcome in protocols that utilize highdose chemotherapy plus autologons blood products as a consolidation maneuver. The monoclonal antibodies which permit this defection may themselves be of value in 'purging' unwanted tumor cells from these collections. It may soon become practical to eliminate amplified genes which are associated with drug resistance and/or confer a further growth advantage on tumor cells, through the use of agents like hydroxyurea that can selectively eliminate extrachromosomal DNA. The role of recombinant hematopoietic growth factors in SCLC treatment remains unclear at present. Applying the lessons of molecular biology, it may become possible to promote differentiation of SCLC, or at least to prevent its conversion to the variant phenotype associated with increased c-myc expression, with the use of trans-RA or related compounds. 'Broad-spectrum' antagonists of neuropeptide function may be effective and relatively specific inhibitors of autocrine stimulation in SCLC, but toxicity is yet unknown. Finally, biologic response modification may be of use in patients who have had their initial tumor burden reduced by standard therapy, utilizing IL-2 (if it can be made less toxic) or monoclonal antibodies conjugated to a toxin or radioemitter (if they can be made more specific).",
keywords = "Dose response, Hyperfractionated irradiation, Immunotherapy, Monoclonal antibodies, Recombinant hematopoietic growth factors, Retinoids, Small cell lung cancer, Tumor necrosis factor",
author = "Livingston, {Robert B}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "255--260",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Small cell lung cancer

T2 - From the laboratory to the clinic

AU - Livingston, Robert B

PY - 1994

Y1 - 1994

N2 - Radiation therapy may be made more effective for SCLC by modifying dose fractionation, based on laboratory observation that SCLC cell lines are often relatively deficient in the ability to recover from doses of 2 Gy or less. Results of this approach will be known within a year. Radiation damage to the lungs may be reduced through the use of agents like PTX which can inhibit production of TNF, a likely initial mediator of radiation-related toxicity. Chemotherapy effectiveness may be improved by building on the observation that etoposide is a schedule dependent drug for SCLC lines, now confirmed in part by clinical trials. The ability to detect low orders of contamination by SCLC cells in marrow or blood should make possible more rational evaluation of outcome in protocols that utilize highdose chemotherapy plus autologons blood products as a consolidation maneuver. The monoclonal antibodies which permit this defection may themselves be of value in 'purging' unwanted tumor cells from these collections. It may soon become practical to eliminate amplified genes which are associated with drug resistance and/or confer a further growth advantage on tumor cells, through the use of agents like hydroxyurea that can selectively eliminate extrachromosomal DNA. The role of recombinant hematopoietic growth factors in SCLC treatment remains unclear at present. Applying the lessons of molecular biology, it may become possible to promote differentiation of SCLC, or at least to prevent its conversion to the variant phenotype associated with increased c-myc expression, with the use of trans-RA or related compounds. 'Broad-spectrum' antagonists of neuropeptide function may be effective and relatively specific inhibitors of autocrine stimulation in SCLC, but toxicity is yet unknown. Finally, biologic response modification may be of use in patients who have had their initial tumor burden reduced by standard therapy, utilizing IL-2 (if it can be made less toxic) or monoclonal antibodies conjugated to a toxin or radioemitter (if they can be made more specific).

AB - Radiation therapy may be made more effective for SCLC by modifying dose fractionation, based on laboratory observation that SCLC cell lines are often relatively deficient in the ability to recover from doses of 2 Gy or less. Results of this approach will be known within a year. Radiation damage to the lungs may be reduced through the use of agents like PTX which can inhibit production of TNF, a likely initial mediator of radiation-related toxicity. Chemotherapy effectiveness may be improved by building on the observation that etoposide is a schedule dependent drug for SCLC lines, now confirmed in part by clinical trials. The ability to detect low orders of contamination by SCLC cells in marrow or blood should make possible more rational evaluation of outcome in protocols that utilize highdose chemotherapy plus autologons blood products as a consolidation maneuver. The monoclonal antibodies which permit this defection may themselves be of value in 'purging' unwanted tumor cells from these collections. It may soon become practical to eliminate amplified genes which are associated with drug resistance and/or confer a further growth advantage on tumor cells, through the use of agents like hydroxyurea that can selectively eliminate extrachromosomal DNA. The role of recombinant hematopoietic growth factors in SCLC treatment remains unclear at present. Applying the lessons of molecular biology, it may become possible to promote differentiation of SCLC, or at least to prevent its conversion to the variant phenotype associated with increased c-myc expression, with the use of trans-RA or related compounds. 'Broad-spectrum' antagonists of neuropeptide function may be effective and relatively specific inhibitors of autocrine stimulation in SCLC, but toxicity is yet unknown. Finally, biologic response modification may be of use in patients who have had their initial tumor burden reduced by standard therapy, utilizing IL-2 (if it can be made less toxic) or monoclonal antibodies conjugated to a toxin or radioemitter (if they can be made more specific).

KW - Dose response

KW - Hyperfractionated irradiation

KW - Immunotherapy

KW - Monoclonal antibodies

KW - Recombinant hematopoietic growth factors

KW - Retinoids

KW - Small cell lung cancer

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0028271543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028271543&partnerID=8YFLogxK

M3 - Article

C2 - 8166464

AN - SCOPUS:0028271543

VL - 14

SP - 255

EP - 260

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -